The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.

På svenska

Author

  • Wende Hao
  • Xuhui Zhang
  • Bingshui Xiu
  • Xiqin Yang
  • Shuofeng Hu
  • Zhiqiang Liu
  • Cuimi Duan
  • Shujuan Jin
  • Xiaomin Ying
  • Yanfeng Zhao
  • Xiaowei Han
  • Xiaopeng Hao
  • Yawen Fan
  • Heather Johnson
  • Di Meng
  • Jenny L Persson
  • Heqiu Zhang
  • XiaoYan Feng
  • Yan Huang
Show all

Summary, in English

Breast cancer is the most common cancer in women worldwide, identification of new biomarkers for early diagnosis and detection will improve the clinical outcome of breast cancer patients. In the present study, we determined serum levels of vitronectin (VN) in 93 breast cancer patients, 30 benign breast lesions, 9 precancerous lesions, and 30 healthy individuals by enzyme-linked immunosorbent assays. Serum VN level was significantly higher in patients with stage 0-I primary breast cancer than in healthy individuals, patients with benign breast lesion or precancerous lesions, as well as those with breast cancer of higher stages. Serum VN level was significantly and negatively correlated with tumor size, lymph node status, and clinical stage (p < 0.05 in all cases). In addition, VN displayed higher area under curve (AUC) value (0.73, 95 % confidence interval (CI) [0.62-0.84]) than carcinoembryonic antigen (CEA) (0.64, 95 % CI [0.52-0.77]) and cancer antigen 15-3 (CA 15-3) (0.69, 95 % CI [0.58-0.81]) when used to distinguish stage 0-I cancer and normal control. Importantly, the combined use of three biomarkers yielded an improvement in receiver operating characteristic curve with an AUC of 0.83, 95 % CI [0.74-0.92]. Taken together, our current study showed for the first time that serum VN is a promising biomarker for early diagnosis of breast cancer when combined with CEA and CA15-3.

Department/s

Publishing year

2016-01-11

Language

English

Publication/Series

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Document type

Journal article

Publisher

Springer

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Experimental Cancer Research, Malmö

ISBN/ISSN/Other

  • ISSN: 1423-0380